167 related articles for article (PubMed ID: 38345769)
21. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
Sandhu J; Wang C; Fakih M
J Natl Compr Canc Netw; 2020 Feb; 18(2):116-119. PubMed ID: 32023524
[TBL] [Abstract][Full Text] [Related]
22. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
23.
Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
[TBL] [Abstract][Full Text] [Related]
24. Rates of
Gottesdiener LS; O'Connor S; Busam KJ; Won H; Solit DB; Hyman DM; Shoushtari AN
Clin Cancer Res; 2018 Dec; 24(23):5815-5819. PubMed ID: 30093446
[TBL] [Abstract][Full Text] [Related]
25. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.
Lin CY; Yu CJ; Shen CI; Liu CY; Chao TC; Huang CC; Tseng LM; Lai JI
Med Oncol; 2022 Sep; 39(12):242. PubMed ID: 36180600
[TBL] [Abstract][Full Text] [Related]
26.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
27. Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric Cancer.
Yamaguchi K; Ito M; Isobe T; Koreishi S; Taguchi R; Uehara K; Ueno S; Imajima T; Kitazono T; Tsuchihashi K; Ohmura H; Yoshihiro T; Tanoue K; Nishiyori S; Iwama E; Maeda T; Akashi K; Baba E
JCO Precis Oncol; 2024 May; 8():e2300681. PubMed ID: 38748981
[TBL] [Abstract][Full Text] [Related]
28. [Targeting HER2 in colorectal cancer].
Spitzer E; Cervera P; André T; Cohen R
Bull Cancer; 2023 Apr; 110(4):402-411. PubMed ID: 36870811
[TBL] [Abstract][Full Text] [Related]
29. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
30. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.
Gong J; Cho M; Sy M; Salgia R; Fakih M
Oncotarget; 2017 Jun; 8(26):42198-42213. PubMed ID: 28178681
[TBL] [Abstract][Full Text] [Related]
31. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
[TBL] [Abstract][Full Text] [Related]
32. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
Siravegna G; Lazzari L; Crisafulli G; Sartore-Bianchi A; Mussolin B; Cassingena A; Martino C; Lanman RB; Nagy RJ; Fairclough S; Rospo G; Corti G; Bartolini A; Arcella P; Montone M; Lodi F; Lorenzato A; Vanzati A; Valtorta E; Cappello G; Bertotti A; Lonardi S; Zagonel V; Leone F; Russo M; Balsamo A; Truini M; Di Nicolantonio F; Amatu A; Bonazzina E; Ghezzi S; Regge D; Vanzulli A; Trusolino L; Siena S; Marsoni S; Bardelli A
Cancer Cell; 2018 Jul; 34(1):148-162.e7. PubMed ID: 29990497
[TBL] [Abstract][Full Text] [Related]
33. Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.
Strickler JH; Hsu LI; Wright P; Stecher M; Siadak MF; Palanca-Wessels MC; Yu J; Zhang N; Espenschied CR; Lang K; Bekaii-Saab TS
J Natl Compr Canc Netw; 2023 Aug; 21(8):805-812.e1. PubMed ID: 37549907
[TBL] [Abstract][Full Text] [Related]
34. Detection of
Lee J; Franovic A; Shiotsu Y; Kim ST; Kim KM; Banks KC; Raymond VM; Lanman RB
Front Oncol; 2019; 9():212. PubMed ID: 31019892
[No Abstract] [Full Text] [Related]
35. RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.
Lee SM; Oh H
Sci Rep; 2024 May; 14(1):11432. PubMed ID: 38763942
[TBL] [Abstract][Full Text] [Related]
36. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
37. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Valtorta E; Martino C; Sartore-Bianchi A; Penaullt-Llorca F; Viale G; Risio M; Rugge M; Grigioni W; Bencardino K; Lonardi S; Zagonel V; Leone F; Noe J; Ciardiello F; Pinto C; Labianca R; Mosconi S; Graiff C; Aprile G; Frau B; Garufi C; Loupakis F; Racca P; Tonini G; Lauricella C; Veronese S; Truini M; Siena S; Marsoni S; Gambacorta M
Mod Pathol; 2015 Nov; 28(11):1481-91. PubMed ID: 26449765
[TBL] [Abstract][Full Text] [Related]
38. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.
Corti G; Bartolini A; Crisafulli G; Novara L; Rospo G; Montone M; Negrino C; Mussolin B; Buscarino M; Isella C; Barault L; Siravegna G; Siena S; Marsoni S; Di Nicolantonio F; Medico E; Bardelli A
Clin Colorectal Cancer; 2019 Jun; 18(2):91-101.e3. PubMed ID: 30981604
[TBL] [Abstract][Full Text] [Related]
39. HER2 in Colorectal Carcinoma: Are We There yet?
Nowak JA
Surg Pathol Clin; 2020 Sep; 13(3):485-502. PubMed ID: 32773196
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
